Insider Selling: GlaxoSmithKline plc (GSK) Insider Sells £142,675.28 in Stock

GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley sold 9,053 shares of the firm’s stock in a transaction on Monday, February 18th. The stock was sold at an average price of GBX 1,576 ($20.59), for a total transaction of £142,675.28 ($186,430.52).

Emma Walmsley also recently made the following trade(s):

  • On Friday, February 15th, Emma Walmsley sold 66,159 shares of GlaxoSmithKline stock. The shares were sold at an average price of GBX 1,585 ($20.71), for a total transaction of £1,048,620.15 ($1,370,207.96).
  • On Thursday, January 10th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The stock was bought at an average price of GBX 1,524 ($19.91) per share, for a total transaction of £121.92 ($159.31).
  • On Tuesday, December 11th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The stock was bought at an average price of GBX 1,494 ($19.52) per share, for a total transaction of £119.52 ($156.17).

Shares of GlaxoSmithKline stock opened at GBX 1,538 ($20.10) on Friday. GlaxoSmithKline plc has a 52 week low of GBX 1,235.20 ($16.14) and a 52 week high of GBX 1,724.50 ($22.53).

The firm also recently announced a dividend, which will be paid on Thursday, April 11th. Stockholders of record on Thursday, February 21st will be issued a GBX 23 ($0.30) dividend. This is an increase from GlaxoSmithKline’s previous dividend of $19.00. The ex-dividend date of this dividend is Thursday, February 21st. This represents a dividend yield of 1.49%.

Several research firms have weighed in on GSK. UBS Group set a GBX 1,700 ($22.21) target price on shares of GlaxoSmithKline and gave the company a “buy” rating in a report on Wednesday, January 2nd. HSBC upped their target price on shares of GlaxoSmithKline from GBX 1,820 ($23.78) to GBX 1,860 ($24.30) and gave the stock a “buy” rating in a research note on Thursday, February 7th. Deutsche Bank set a GBX 1,520 ($19.86) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research report on Tuesday, February 12th. Barclays cut shares of GlaxoSmithKline to an “equal weight” rating in a report on Wednesday, December 5th. Finally, Credit Suisse Group set a GBX 1,600 ($20.91) target price on shares of GlaxoSmithKline and gave the company a “neutral” rating in a report on Monday, December 17th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus price target of GBX 1,520.93 ($19.87).

TRADEMARK VIOLATION NOTICE: “Insider Selling: GlaxoSmithKline plc (GSK) Insider Sells £142,675.28 in Stock” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.thelincolnianonline.com/2019/02/22/insider-selling-glaxosmithkline-plc-gsk-insider-sells-142675-28-in-stock.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: What is a Candlestick Chart?

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply